CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $20M, lower than 95% of all stocks globally
- PositionCurrent ratio is 27.08×, higher than 95% of its Biotechnology peers (median 5.64×)
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
2.04BUSDvs all stocks (USD)
Revenue (TTM)
20.00MUSDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
0.9480xvs all stocks
52-Week Change
196.18%vs all stocks
Market Capitalization
2.04BUSDvs all stocks (USD)
Enterprise Value
1.45BUSDvs all stocks (USD)
Forward P/E
-9.69xvs Biotechnology peers
Price to Book (MRQ)
4.32xvs Biotechnology peers
Enterprise to Revenue
72.67xvs Biotechnology peers
Enterprise to EBITDA
-11.99xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
-121.08%vs Biotechnology peers
Return on Assets (TTM)
-19.10%vs Biotechnology peers
Return on Equity (TTM)
-28.33%vs Biotechnology peers
Revenue (TTM)
20.00MUSDvs all stocks (USD)
Revenue per Share (TTM)
0.4770USDUpdated Jul 19, 2026Gross Profit (TTM)
6.86MUSDvs all stocks (USD)
EBITDA (TTM)
-121.21MUSDvs all stocks (USD)
Net Income (TTM)
-107.28MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-80.30MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-49.43MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00USDFY2025 · Dec 31, 2025Operating Income
-125.10MUSDvs all stocks (USD)
Pre-tax Income
-111.48MUSDFY2025 · Dec 31, 2025Net Income
-111.48MUSDFY2025 · Dec 31, 2025EBIT
-125.10MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-124.08MUSDFY2025 · Dec 31, 2025Research & Development
94.79MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
30.31MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
13.62MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-111.48MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-88.65MUSDFY2025 · Dec 31, 2025Free Cash Flow
-89.26MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
52.75MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-111.48MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
1.02MUSDFY2025 · Dec 31, 2025Stock-based Compensation
18.86MUSDFY2025 · Dec 31, 2025Other Non-cash Items
2.03MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
2.21MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-1.28MUSDFY2025 · Dec 31, 2025Capital Expenditures
-616.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-354.78MUSDFY2025 · Dec 31, 2025Sale of Investments
167.93MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-187.47MUSDFY2025 · Dec 31, 2025Common Stock Repurchase
-1.00KUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
269.44MUSDFY2025 · Dec 31, 2025Shares Outstanding
47.81MSharesUpdated Jul 19, 2026Float Shares
31.78MSharesUpdated Jul 19, 2026Shares Short
2.26MSharesUpdated Jul 19, 2026Short Ratio
5.61daysvs all stocks
Short % of Shares Outstanding
7.49%vs all stocks
% Held by Insiders
4.60%vs all stocks
% Held by Institutions
109.56%vs all stocks
Total Cash (MRQ)
476.78MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
9.97USDUpdated Jul 19, 2026Total Debt (MRQ)
10.80MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0229xvs Biotechnology peers
Current Ratio (MRQ)
27.08xvs Biotechnology peers
Book Value per Share (MRQ)
9.86USDUpdated Jul 19, 2026Total Assets
512.43MUSDvs all stocks (USD)
Total Current Assets
498.56MUSDFY2025 · Dec 31, 2025Total Liabilities
27.78MUSDFY2025 · Dec 31, 2025Total Non-current Assets
13.87MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
8.73MUSDFY2025 · Dec 31, 2025Total Current Liabilities
19.05MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
52.65MUSDFY2025 · Dec 31, 2025Other Short-term Investments
437.89MUSDFY2025 · Dec 31, 2025Accounts Payable
4.19MUSDFY2025 · Dec 31, 2025Short-term Debt
2.75MUSDFY2025 · Dec 31, 2025Long-term Debt
8.73MUSDFY2025 · Dec 31, 2025Common Stock (Book)
48.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-235.23MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
484.65MUSDvs all stocks (USD)
52-Week Low
13.62USDUpdated Jul 19, 202652-Week High
43.76USDUpdated Jul 19, 202652-Week Change
196.18%vs all stocks
Beta
0.9480xvs all stocks
50-Day MA
38.30USDUpdated Jul 19, 2026200-Day MA
31.34USDUpdated Jul 19, 2026Avg 10-Day Volume
442.45KSharesUpdated Jul 19, 2026Avg 30-Day Volume
422.73KSharesUpdated Jul 19, 2026Diluted EPS (TTM)
-2.60USDUpdated Jul 19, 20261 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Low-Leverage Liquidity Configuration
Cash on hand covers most or all of its debt, and its equity share of assets is high for its industry.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Current ratio is 27.08×, higher than 95% of its Biotechnology peers (median 5.64×)Significant
Current ratio: 27.08Industry median: 5.64Industry P95: 23.02Peers compared: 261
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.68
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $20M, lower than 95% of all stocks globallySignificant
Revenue (USD): 20,000,000Global P5: 30,274,777.221
Market cap is $2.04B, above the global median of $1.15BNotable
Market cap (USD): 2,038,383,713Global Median: 1,146,734,693.424
Companies that share the same coordination system — how they create, deliver, or capture value.
Adma Biologics Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Caplin Point Laboratories Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule
Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Aurinia Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Sk Bioscience Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Syndax Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Nuvation Bio Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Tibet Rhodiola Pharmaceutical Holding Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Medicine Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Mabwell (Shanghai) Bioscience Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Apogee Therapeutics Inc.
1 interpretationLow-Leverage Liquidity Configuration
China Nonferrous Mining Corporation Limited
1 interpretationLow-Leverage Liquidity Configuration
Divgi Torqtransfer Systems Limited
1 interpretationLow-Leverage Liquidity Configuration